Online Impact
Statistics from Altmetric.com
ARTICLE USAGE
Cited By
Article Information
Volume 6, Issue 1, pp. 51-60
PubMed
Published By
Print ISSN
Online ISSN
History
- November 16, 2006
- March 17, 2006
- October 6, 2006
- Published first January 11, 2007.
Article Versions
- Previous version (January 11, 2007 - 13:49).
- You are viewing the most recent version of this article.
Copyright & Usage
American Association for Cancer Research
Author Information
- Deborah L. Marrocco1,
- Wayne D. Tilley1,
- Tina Bianco-Miotto1,
- Andreas Evdokiou2,
- Howard I. Scher3,
- Richard A. Rifkind4,
- Paul A. Marks4,
- Victoria M. Richon5 and
- Lisa M. Butler1
- 1Dame Roma Mitchell Cancer Research Laboratories, Department of Medicine, University of Adelaide, Hanson Institute, Adelaide, South Australia, Australia; 2Department of Orthopaedics and Trauma, Royal Adelaide Hospital, Adelaide, South Australia, Australia; 3Genitourinary Oncology Service, and 4Cell Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 5Merck & Co., Inc., Boston, Massachusetts
- Requests for reprints: Lisa M. Butler, Dame Roma Mitchell Cancer Research Laboratories, Department of Medicine, University of Adelaide, Hanson Institute, Adelaide, South Australia 5000, Australia. Phone: 618-8222-3270; Fax: 618-8222-3217. E-mail: lisa.butler{at}imvs.sa.gov.au
January 2007
Volume 6, Issue 1
Volume 6, Issue 1
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation
Jump to section
Advertisement